Quantum-Si Proteus Beats Platinum Pro 30x in Interim Data

Quantum-Si Incorporated (Nasdaq: QSI) announced on 28 September 2026 that its next-generation Proteus platform delivered a median of 30 times more alignments than its commercial Platinum Pro instrument from a single chamber, using a developmental sequencing kit that detects 18 amino acids. The company also reported a 4.8-fold lower median false discovery rate, 1.36% versus 6.58%, and said Proteus identified all six control peptides in every run. The data are interim and the instrument, consumable, loading protocol and analysis software remain in development.

Context — why this matters for QSI shareholders

The comparison the company supplied is against its own commercial product, Platinum Pro, rather than a competitor instrument. That makes the release a measure of internal generational progress, not market share. Quantum-Si said the Proteus system has not been fully optimized, which means the gap to its own prior platform could widen before launch.

The company has guided Proteus to launch in the second quarter of 2027 and expects the commercial kit to detect all 20 amino acids at launch. The current developmental kit detects 18. The delta between 18 and 20 is one of the remaining technical milestones the company flagged in its forward-looking statement.

Macro conditions are not the driver here. This is a single-product development update from a pre-commercial-revenue proteomics company, and the relevant benchmark is the company's own prior instrument, not an index or a rate level. The report gives no broader market context and none should be inferred.

The catalyst chain is straightforward. Quantum-Si has been working through organizational changes, cost-control actions and a reduction in force, disclosed in prior filings referenced in the report. Interim data that shows a step change in performance supports the commercial case for Proteus while the company manages its cash runway.

The timing is tied to the World HUPO Congress in Singapore. Jeff Hawkins, President and Chief Executive Officer, is scheduled to present at a lunchtime seminar on Tuesday, 29 September 2026 at 12:15 Singapore Time in Room 330. A copy of the presentation will be posted to the investor relations site, with an audio recording added once available.

Data — what the numbers show

The control peptide study was designed to test fundamental performance independent of sample preparation. The company reported a median of 30x more alignments per single chamber for Proteus, with n = 4 runs per platform. Proteus identified all six control peptides in every run. The median false discovery rate fell to 1.36% from 6.58% on Platinum Pro.

Based on the single-chamber results, the company projects that a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. That figure is a projection, not a measured result.

Metric	Platinum Pro	Proteus (interim)
Median alignments per single chamber	baseline	30x
Median false discovery rate	6.58%	1.36%
Control peptides identified	6	6 every run
Projected full-run alignments	two-chamber baseline	~60x

In protein mixtures prepared with a commercial library prep kit, Proteus identified 1.6 to 2.0 times more peptides than Platinum Pro. On a 24-protein panel not previously sequenced on either platform, Proteus detected all 24 proteins versus an average of 20.3 on Platinum Pro, and detected 4.3 times more amino acids per run. Per-residue detection was higher across the amino acids measured, including cysteine and histidine, which the company said were detected only on Proteus. The report gives no peer or sector comparison, so none is presented here.

Analysis — what it means for proteomics-adjacent tickers

The read-through sits inside the life-sciences tools complex rather than broad healthcare. Companies that sell benchtop sequencers and consumables compete on data quality per run, and a platform that claims 30x the alignments from a single chamber and a lower false discovery rate compresses the value of incumbent throughput claims. The report does not name any competitor, so the exposure is thematic, not specific.

The second-order effect runs through consumables, not instruments. Higher alignments per chamber and more peptides per prep mean more kit volume per experiment, which is where recurring revenue typically sits for this category. The company did not disclose pricing, kit economics or attach rates, so the revenue math cannot be sized from this release.

The limitation is material. These are interim results on a developmental kit that detects 18 amino acids, not the 20 the company expects at launch. The instrument, consumable, loading protocol and analysis software are not fully optimized, and the 60x figure is a projection from single-chamber data. Verification, validation and launch-readiness work remains outstanding, and the company's own risk language flags that additional technical or integration challenges may arise or cost more to address than expected.

Positioning around QSI has been tied to the Proteus launch timeline rather than current Platinum Pro revenue. Traders who are long the name are underwriting an execution story with a defined date. Short interest data, options positioning and borrow rates are not in the report or the market data provided, so the flow direction cannot be quantified here.

Outlook — what to watch next

The first catalyst is the presentation itself on 29 September 2026 at the World HUPO Congress in Singapore, followed by the posting of the slide deck and an audio recording on the investor relations site. Hawkins will be speaking directly to the proteomics research community, which is the buyer base for the platform.

The second is the transition from the 18-amino-acid developmental kit to the 20-amino-acid commercial kit the company expects at launch. That is the gating technical milestone before the second-quarter 2027 launch window.

The third is any update on system integration, optimization, verification and validation, and on the cash runway the company cited in its forward-looking language. The report gives no specific level or date for those checkpoints. No price levels are provided in the report or the market data, so none are offered.

Frequently Asked Questions

What does the 30x alignment figure actually measure?

Alignments are the number of times sequencing reads can be matched to a known peptide or protein reference within a run. A higher count means more usable data per chamber, which supports deeper protein sequence coverage. Quantum-Si reported the median was 30 times higher on Proteus than on Platinum Pro across four runs per platform in a control peptide study designed to isolate fundamental performance from sample preparation effects.

Is Proteus available to buy today?

No. The company said the Proteus instrument, consumable, loading protocol and analysis software are still in development and not yet fully optimized. Quantum-Si has guided Proteus to launch in the second quarter of 2027 and expects the commercial kit to detect all 20 amino acids at launch, versus the 18 amino acids the developmental kit used in these interim results detects.

Why does the false discovery rate matter more than the alignment count?

False discovery rate measures the share of identifications that are likely wrong. A 1.36% median rate on Proteus versus 6.58% on Platinum Pro means roughly one in 74 calls versus one in 15. For research workflows where a misidentified peptide can invalidate downstream conclusions, a lower error rate is what makes a higher alignment count usable rather than just larger.

Bottom Line

Quantum-Si's interim data show Proteus is a generational leap over Platinum Pro on the company's own measures, but the platform is unoptimized and the 60x full-run figure is a projection, not a result.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.